'%3E%3Cpath d='M16.3574 35.6519H12.9537L15.0491 18.8873L16.3574 35.6519ZM30.4229 54.0093L22.309 0.994385H7.91795L0 54.0093H10.6634L11.5802 46.3855H17.4014L17.9914 54.0093H30.4229Z' fill='%23971B20'/%3E%3Cpath d='M48.2073 41.8813C48.2073 43.4049 47.4892 44.0011 46.1144 44.0011H43.7595V11.0687H46.1144C47.4892 11.0687 48.2073 11.6636 48.2073 13.1885V41.8813ZM59.5273 43.6695V11.3326C59.5273 3.71323 53.5729 0.994385 47.8157 0.994385H31.7213V54.0093H47.8157C53.5729 54.0093 59.5273 51.29 59.5273 43.6695Z' fill='%23971B20'/%3E%3Cpath d='M90.183 0.994385H78.6039L75.0711 30.6157L71.9955 0.994385H59.4346L69.2474 54.0093H80.373L90.183 0.994385Z' fill='%23971B20'/%3E%3Cpath d='M107.063 42.3448C107.063 43.7359 105.951 44.5974 104.643 44.5974C103.269 44.5974 102.157 43.7359 102.157 42.3448V12.658C102.157 11.2676 103.269 10.4058 104.643 10.4058C105.951 10.4058 107.063 11.2676 107.063 12.658V42.3448ZM119.233 43.2723V11.7312C119.233 6.36384 112.952 -3.8147e-06 104.643 -3.8147e-06C96.2667 -3.8147e-06 89.9867 6.36384 89.9867 11.7312V43.2723C89.9867 48.6393 96.2667 55 104.643 55C112.952 55 119.233 48.6393 119.233 43.2723Z' fill='%23971B20'/%3E%3Cpath d='M150.976 43.9349V33.7309H139.069V42.3448C139.069 43.7359 137.957 44.5974 136.582 44.5974C135.076 44.5974 133.964 43.7359 133.964 42.3448V12.658C133.964 11.2676 135.076 10.4058 136.582 10.4058C137.957 10.4058 139.069 11.2676 139.069 12.658V21.2723H150.976V11.0687C150.976 5.70107 145.283 -3.8147e-06 136.582 -3.8147e-06C127.75 -3.8147e-06 121.796 5.70107 121.796 11.0687V43.9349C121.796 49.3022 127.75 55 136.582 55C145.283 55 150.976 49.3022 150.976 43.9349Z' fill='%23971B20'/%3E%3Cpath d='M167.478 35.6519H164.076L166.17 18.8873L167.478 35.6519ZM181.544 54.0093L173.432 0.994385H159.037L151.123 54.0093H161.785L162.704 46.3855H168.523L169.114 54.0093H181.544Z' fill='%23971B20'/%3E%3Cpath d='M205.412 10.4058V0.994385H177.081V10.4058H185.392V54.0093H197.428V10.4058H205.412Z' fill='%23971B20'/%3E%3Cpath d='M230.002 54.0093V43.9349H218.914V31.8746H226.635V21.8028H218.914V10.4058H230.002V0.994385H206.875V54.0093H230.002Z' fill='%23971B20'/%3E%3C/g%3E%3Cdefs%3E%3CclipPath id='clip0_260_7080'%3E%3Crect width='230' height='55' fill='white'/%3E%3C/clipPath%3E%3C/defs%3E%3C/svg%3E){kind=small}
GlaxoSmithKline in late July contacted health care providers across the country to inform them that the combination of the company's anti-HIV drugs Epivir (3TC) and Ziagen with Gilead Sicences' Viread appears to be significantly less potent than other combinations of anti-HIV medications. The company wrote that a high rate of early virologic nonresponse was seen among HIV-positive people taking that combination of antiretrovirals in a Glaxo-sponsored clinical study of a new 3TC-Ziagen combination pill. Based on early study results, Glaxo does not recommend the use of 3TC and Ziagen in combination with Viread for either treatment-naive or treatment-experienced patients. The company also recommends that any patients currently taking this combination of drugs be closely watched for signs of treatment failure and that patients on this combination be evaluated for a possible regimen change. Glaxo terminated the 3TC-Ziagen-Viread arm of the study based on the preliminary treatment failure data.
